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Introduction
Pertussis, also known as whooping cough, is a highly contagious disease caused by the bacterium Bordetella pertussis. It is generally thought to be under-diagnosed and remains the least well controlled of all the vaccine preventable diseases targeted by the Australian National Immunisation Program. 1 Epidemics occur every 3-4 years. This is despite immunisation continuing to increase, with more than 90% of one-year-olds being fully vaccinated.
The literature suggests that epidemics result from waning immunity in later childhood and adolescence. The peak incidence of whooping cough in Australia occurs in adolescents and adults with more than 70% of pertussis notifications occurring in people older than 15 years in 2004-05. Data suggest that 10-35% of subacute coughing illnesses in adults are due to pertussis infection. 2 Death in individuals older than 10 years of age is rare and non-immunised infants remain the most likely group to have severe life-threatening disease requiring hospitalisation. 1 
Clinical presentation
The classic presentation of pertussis is one of spasms of coughing with a characteristic inspiratory whoop. However, this is less common in older children and adults. The first 1-2 weeks of illness with B. pertussis resembles other upper respiratory tract infections, with runny nose and mild cough. This is followed by the paroxysmal coughing phase in the second and third weeks.
Diagnosis
As classic symptoms of whooping cough do not usually exist PCR-based testing is the most sensitive and specific of all investigations, particularly early in the illness. It is sensitive for longer than culture and is less likely to be affected by antibiotic treatment (0% detection via culture after seven days antibiotics). 3 Although direct immunofluorescence is highly specific, it has limited sensitivity. Its main advantage is speed.
Antibiotic treatment
Antibiotics are recommended in the initial catarrhal phase of infection when they are effective in eliminating B. pertussis from the nasopharynx and reducing the infectious period. 
Symptomatic treatment
A Cochrane review found that some symptomatic treatments for the cough associated with pertussis had no clear benefits. 5 The treatments reviewed included antihistamines, dexamethasone, salbutamol and pertussis immunoglobulin. It is possible that immunoglobulin offers some improvement in mean number of whoops, but further well-designed good quality trials need to be developed to determine this. It is suggested that prophylaxis be given as soon as possible, but within three weeks of symptom onset in the infected contact. The dose and duration of antibiotics for prophylaxis are the same as for treatment (see Table 1 ).
As three or more injections are required to confer protection, infant vaccination is not helpful in controlling a pertussis outbreak. 1 However, unvaccinated contacts aged eight years or older can be offered a diphtheria, tetanus and acellular pertussis vaccine and younger contacts can be given a catch-up course. 
Conclusion
When B. pertussis is diagnosed early in the illness, antibiotics can decrease the infectious period, but have no effect on the duration or severity of disease. Antibiotic prophylaxis with macrolides, such as clarithromycin and azithromycin, is recommended for certain high-risk contacts. Symptomatic treatment of cough has not been proven to be significantly helpful in decreasing B. pertussis cough. Adolescent and adult booster immunisation remains critical for preventing disease outbreaks.
